Patent EP0120165A2 successfully refreshed from Google Patents.
EP0120165A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
A preparation and a process for achieving regional weight control
Assignee: Individual
•
Filing: 1983-12-09
•
Granted: —
•
Expires: 2003-12-09
Abstract
Abstract A treatment for accelerating regional weight reduction in humans, wherein an active ingredient encouraging elimination of fatty deposits, preferably a beta adrenergic stimulator or an alpha-2 adrenergic inhibitor, is selectively delivered to a regional far deposit prior to commencing or during a general weight control program, whereby body weight is preferentially reduced in the selected area. The beta adrenergic stimulator, preferably isoproterenol or foreskolin, or the alpha-2 adrenergic inhibitor, preferably yohimbine, or combinations thereof may be delivered by any means accomplishing specific delivery to the selected area, including injection, implantation, and topical application to the skin as in an ointment or creme.
Inventors
- 👤 Frank L. Greenway Iii
- 👤 George A. Bray
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-09 16:49
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0014; A61K31/00; A61K31/13; A61K31/135; A61K31/33; A61K31/395; A61K31/41; A61K31/435; A61K31/47; A61K31/475; A61K31/48; A61K31/495; A61K31/505; A61K31/519; A61K31/52; A61K8/00; A61K8/18; A61K8/30; A61K8/40; A61K8/41; A61K8/49; A61K8/494; A61K8/4953; A61K8/4973; A61K8/498; A61K9/0019; A61P; A61P3/00; A61P3/06; A61Q; A61Q19/00; A61Q19/06
Claims Analysis
Total Claims: 41
Claim 1
Independent Claim
32 words
A preparation for application to selected parts of an animal to encourage local reduction of regional fat deposits, which preparation comprises at least one active ingredient for encouraging reduction of fat cells.
Claim 2
Dependent Claim
32 words
A preparation for application to selected parts of an animal to encourage local reduction of regional fat deposits, which preparation comprises at least one active ingredient for encouraging reduction of fat cells.
Claim 3
Dependent Claim
16 words
A preparation according to claim 1, specifically for application to selected parts of a human body.
Claim 4
Dependent Claim
18 words
A preparation according to claim I or 2, which further comprises a suitable carrier for the active ingredient.
Claim 5
Dependent Claim
21 words
A preparation according to claim 3, wherein said carrier is a liquid and the preparation is suitable for administration by injection.
Claim 6
Dependent Claim
29 words
A preparation according to any one of claims I to 4, wherein said active ingredient is selected from a beta adrenergic stimulator, an alpha-2 adrenergic inhibitor, and combinations thereof.
Claim 7
Dependent Claim
35 words
A preparation according to any one of claims I to 5, wherein said active ingredient is selected from theophylline, isoproterenol, forskolin, epinephrine, yohimbine, rauwolscine, piperoxane, phentolamine, dihydroergotamine, and any combinations of two or more thereof.
Claim 8
Dependent Claim
24 words
A preparation according to any one of claims I to 6, wherein the active ingredients are forskolin and yohimbine, and the carrier is aquaphor.
Claim 9
Dependent Claim
57 words
An ointment for topical application to the skin to encourage local reduction of regional fat deposits during a general weight reduction program, which ointment comprises at least one active ingredient for encouraging reduction of fat cells; and a carrier for the active ingredient, the carrier allowing regionally selective topical application to the skin over the fat deposits.
Claim 10
Dependent Claim
57 words
An ointment for topical application to the skin to encourage local reduction of regional fat deposits during a general weight reduction program, which ointment comprises at least one active ingredient for encouraging reduction of fat cells; and a carrier for the active ingredient, the carrier allowing regionally selective topical application to the skin over the fat deposits.
Claim 11
Dependent Claim
24 words
An ointment according to claim 8, wherein said active ingredient is selected from a beta adrenergic stimulator, an alpha-2 adrenergic inhibitor, and combinations thereof.
Claim 12
Dependent Claim
32 words
An ointment according to claim 8 or 9, wherein said active ingredient is selected from theophylline, isoproterenol, forskolin, epinephrine, yohimbine, rauwolscine, piperoxane, phentolamine, dihydroergotamine, and any combinations of two or more thereof.
Claim 13
Dependent Claim
24 words
An ointment according to any one of claims 8 to 10, wherein the active ingredients are forskolin and yohimbine, and the carrier is aquaphor.
Claim 14
Dependent Claim
48 words
A pharmaceutical preparation for reducing regional fat deposits in a weight reducing program, which preparation comprises at least one active ingredient for encouraging reduction of fat cells and a carrier for the active ingredient, the carrier allowing selective introduction of the active ingredient into the regional fat deposit.
Claim 15
Dependent Claim
48 words
A pharmaceutical preparation for reducing regional fat deposits in a weight reducing program, which preparation comprises at least one active ingredient for encouraging reduction of fat cells and a carrier for the active ingredient, the carrier allowing selective introduction of the active ingredient into the regional fat deposit.
Claim 16
Dependent Claim
13 words
A preparation according to claim 12, wherein the carrier is a saline solution.
Claim 17
Dependent Claim
26 words
A preparation according to claim 12 or 13, wherein the active ingredient is selected from a beta adrenergic stimulator, and alpha-2 adrenergic inhibitor and combinations thereof.
Claim 18
Dependent Claim
33 words
A preparation according to claim 12, 13 or 14, wherein said active ingredient is selected from theophylline, isoproterenol, forskolin, epinephrine, yohimbine, rauwolscine, piperoxane, phentolamine, dihydroergotamine, and any combinations of two or more thereof.
Claim 19
Dependent Claim
73 words
A process for achieving a selective reduction in body weight, which process comprises the steps of delivering selectively to the portion of the body where weight reduction is sought an active ingredient selected from a beta adrenergic stimulator, an alpha-2 adrenergic inhibitor, and combinations thereof; and accomplishing a general weight loss program, whereby an acceleration of weight loss is achieved from the portion of the body to which the chemical was selectively delivered.
Claim 20
Dependent Claim
73 words
A process for achieving a selective reduction in body weight, which process comprises the steps of delivering selectively to the portion of the body where weight reduction is sought an active ingredient selected from a beta adrenergic stimulator, an alpha-2 adrenergic inhibitor, and combinations thereof; and accomplishing a general weight loss program, whereby an acceleration of weight loss is achieved from the portion of the body to which the chemical was selectively delivered.
Claim 21
Dependent Claim
16 words
A process according to claim 16, wherein the active ingredient is selectively delivered to the thighs.
Claim 22
Dependent Claim
16 words
A process according to claim 16 or 17, wherein said delivery step is achieved by injection.
Claim 23
Dependent Claim
23 words
A process according to claim 16 or 17, wherein said delivery step is achieved by topical application to the surface of the skin.
Claim 24
Dependent Claim
16 words
A process according to claim 16, 17, 18 or 19, wherein the active ingredient is isoproterenol.
Claim 25
Dependent Claim
49 words
A process for achieving accelerated reduction of a regional fat deposit present in a selected portion of the body, which process comprises the steps of introducing selectively into the regional fat deposit a chemical to encourage reduction of the fatty tissue; and undergoing a program of general weight reduction.
Claim 26
Dependent Claim
49 words
A process for achieving accelerated reduction of a regional fat deposit present in a selected portion of the body, which process comprises the steps of introducing selectively into the regional fat deposit a chemical to encourage reduction of the fatty tissue; and undergoing a program of general weight reduction.
Claim 27
Dependent Claim
29 words
A process according to claim 21, wherein the chemical introduced selectively into the fat deposit is selected from a beta adrenergic stimulator, an alpha-2 adrenergic inhibitor and combinations thereof.
Claim 28
Dependent Claim
18 words
A process according to claim 21 or 22, wherein the chemical introduced encourages lipolysis of the fatty tissue.
Claim 29
Dependent Claim
30 words
A process according to claim 21, 22 or 23, wherein the chemical introduced selectively into the fat deposit is a beta adrenergic stimulator selected from theophylline, isoproterenol, forskolin, and epinephrine.
Claim 30
Dependent Claim
31 words
A process according to claim 21, 22 or 23, wherein the chemical introduced selectively into the fat deposit is an alpha-2 adrenergic inhibitor selected from yohimbine, rauwolscine, piperoxane, phentolamine and dihydroergotamine.
Claim 31
Dependent Claim
18 words
A process according to any one of claims 21 to 25, wherein said chemical is introduced by injection.
Claim 32
Dependent Claim
26 words
A process according to any one of claims 21 to 25, wherein said - chemical is introduced by topical application to the surface of the skin.
Claim 33
Dependent Claim
48 words
A treatment for accelerating the reduction of regional fat deposits in a person undergoing a program of treatment for an overweight condition, which treatment comprises delivering selectively to the portion of the person's body where weight reduction is sought a chemical to encourage reduction of the fatty tissue.
Claim 34
Dependent Claim
48 words
A treatment for accelerating the reduction of regional fat deposits in a person undergoing a program of treatment for an overweight condition, which treatment comprises delivering selectively to the portion of the person's body where weight reduction is sought a chemical to encourage reduction of the fatty tissue.
Claim 35
Dependent Claim
12 words
A treatment according to claim 28, wherein the reduction occurs by lipolysis.
Claim 36
Dependent Claim
26 words
A treatment according to claim 28 or 29, wherein the said chemical is selected from a beta adrenergic stimulator, an aplha-2 adrenergic inhibitor, and combinations thereof.
Claim 37
Dependent Claim
19 words
A treatment according to claim 30, wherein the beta adrenergic stimulator is selectable from theophylline, isoproterenol, forskoiin, and epinephrine.
Claim 38
Dependent Claim
26 words
A treatment according to claim 30 or 31, wherein the alpha-2 adrenergic inhibitor is selectable from the group consisting of yohimbine, rauwolscine, piperoxane, phentolamine, and dihydroergotamine.
Claim 39
Dependent Claim
18 words
A treatment according to any one of claims 28 to 32, wherein said chemical is delivered by injection.
Claim 40
Dependent Claim
25 words
A treatment according to any one of claims 28 to 32, wherein said chemical is delivered by topical application to the surface of the skin.
Claim 41
Dependent Claim
34 words
A treatment according to any one of claims 28 to 34, wherein the portion of the body where accelerated weight reduction is sought is the thighs, and the chemical is delivered to the thighs.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.